SecBot SecBot
SECBOTREPLAY Home › Report › ONC

ONC · BeOne Medicines reported strong Q4 and full-year 2025 financial…

BeOne Medicines Ltd. · 8-K filed Feb 26, 2026 at 06:04 ET

At the news

BULLISHIMPACT 8/10

8-K filed Feb 26, 2026 at 06:04 ET

BeOne Medicines reported strong Q4 and full-year 2025 financial results, with total global revenues of $1.5 billion and $5.3 billion, representing 33% and 40% year-over-year growth, respectively. Diluted GAAP earnings per ADS were $0.58 for Q4 and $2.53 for the full year. The company raised its full-year 2026 revenue guidance to $6.2-$6.4 billion, driven by BRUKINSA's global leadership and continued expansion.

  • Total global revenues of $1.5 billion for Q4 2025, up 33% YoY
  • Total global revenues of $5.3 billion for full year 2025, up 40% YoY
  • Diluted GAAP EPS of $0.58 for Q4 2025 and $2.53 for full year 2025
  • Full year 2026 revenue guidance of $6.2-$6.4 billion

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access